JP2024023235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023235A5 JP2024023235A5 JP2023189307A JP2023189307A JP2024023235A5 JP 2024023235 A5 JP2024023235 A5 JP 2024023235A5 JP 2023189307 A JP2023189307 A JP 2023189307A JP 2023189307 A JP2023189307 A JP 2023189307A JP 2024023235 A5 JP2024023235 A5 JP 2024023235A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomeric compound
- stranded oligomeric
- modified oligonucleotide
- wing segment
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 108091034117 Oligonucleotide Proteins 0.000 claims 10
- 239000002777 nucleoside Substances 0.000 claims 10
- 125000003835 nucleoside group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 claims 2
- 101710194189 Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- NETGOEWJJZQLCO-PKLMIRHRSA-N N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical group C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O.FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 NETGOEWJJZQLCO-PKLMIRHRSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579640P | 2017-10-31 | 2017-10-31 | |
| US62/579,640 | 2017-10-31 | ||
| US201862743669P | 2018-10-10 | 2018-10-10 | |
| US62/743,669 | 2018-10-10 | ||
| JP2020523976A JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ENaC発現の調節因子 |
| PCT/US2018/058354 WO2019089692A1 (en) | 2017-10-31 | 2018-10-31 | MODULATORS OF ENaC EXPRESSION |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523976A Division JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ENaC発現の調節因子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023235A JP2024023235A (ja) | 2024-02-21 |
| JP2024023235A5 true JP2024023235A5 (cg-RX-API-DMAC7.html) | 2024-05-14 |
Family
ID=66333370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523976A Active JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ENaC発現の調節因子 |
| JP2023189307A Pending JP2024023235A (ja) | 2017-10-31 | 2023-11-06 | ENaC発現の調節因子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523976A Active JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ENaC発現の調節因子 |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3990119A4 (en) * | 2019-06-26 | 2024-03-27 | Fred Hutchinson Cancer Center | METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATION THERAPIES FOR THE TREATMENT OF CANCERS AND RELATED DISORDERS |
| PL3956450T3 (pl) | 2019-07-26 | 2025-12-22 | Ionis Pharmaceuticals, Inc. | Związki i sposoby modulowania gfap |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EP2304057B1 (en) * | 2008-06-17 | 2014-09-17 | Signature Diagnostics AG | Method for the detection of ovarian cancer |
| US9574193B2 (en) * | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
| US10590485B2 (en) * | 2014-05-29 | 2020-03-17 | Geneticure Llc | Therapeutic regimen for hypertension |
-
2018
- 2018-10-31 MX MX2020003554A patent/MX2020003554A/es unknown
- 2018-10-31 BR BR112020005038-5A patent/BR112020005038A2/pt not_active Application Discontinuation
- 2018-10-31 WO PCT/US2018/058354 patent/WO2019089692A1/en not_active Ceased
- 2018-10-31 JP JP2020523976A patent/JP7431728B2/ja active Active
- 2018-10-31 TW TW107138481A patent/TW201927313A/zh unknown
- 2018-10-31 SG SG11202001863PA patent/SG11202001863PA/en unknown
- 2018-10-31 CN CN201880058494.5A patent/CN111372594A/zh active Pending
- 2018-10-31 EP EP18874475.9A patent/EP3703702A4/en active Pending
- 2018-10-31 CA CA3074739A patent/CA3074739A1/en not_active Abandoned
- 2018-10-31 US US16/759,908 patent/US20210180057A1/en not_active Abandoned
- 2018-10-31 AU AU2018357932A patent/AU2018357932A1/en not_active Abandoned
- 2018-10-31 KR KR1020207014550A patent/KR20200079505A/ko not_active Ceased
- 2018-10-31 PE PE2020000308A patent/PE20200749A1/es unknown
-
2020
- 2020-03-06 CL CL2020000586A patent/CL2020000586A1/es unknown
- 2020-03-16 CO CONC2020/0003134A patent/CO2020003134A2/es unknown
- 2020-04-26 IL IL274231A patent/IL274231A/en unknown
-
2023
- 2023-10-23 US US18/492,683 patent/US20240327838A1/en not_active Abandoned
- 2023-11-06 JP JP2023189307A patent/JP2024023235A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pley et al. | Model for an RNA tertiary interaction from the structure of an intermolecular complex between a GAAA tetraloop and an RNA helix | |
| CN102123716B (zh) | 用于治疗病毒感染的化合物和方法 | |
| CA2163520C (en) | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents | |
| EP0748330B1 (en) | L-nucleosides for the treatment of hepatitis b-virus and epstein-bar virus | |
| TWI313176B (en) | Pharmaceutical compositions for treating diseases mediated by the hepatitis virus | |
| CN100387237C (zh) | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 | |
| US5631239A (en) | L-2',3'-dideoxy nucleoside analogs as anti-Hepatitis B (HBV) agents | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| CN108350454A (zh) | 等位基因选择性基因编辑及其用途 | |
| TW202113079A (zh) | 經修飾之間隙子寡核苷酸及其使用方法 | |
| JPH05505101A (ja) | オリゴヌクレオチド療法における三重らせん形成 | |
| JP2022501024A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516096A5 (cg-RX-API-DMAC7.html) | ||
| JP2022526267A5 (cg-RX-API-DMAC7.html) | ||
| JP2010500291A5 (cg-RX-API-DMAC7.html) | ||
| JP2025511183A5 (cg-RX-API-DMAC7.html) | ||
| JP2023549563A5 (cg-RX-API-DMAC7.html) | ||
| EP0703787A1 (en) | Cell growth regulators | |
| JP2024520522A5 (cg-RX-API-DMAC7.html) | ||
| Meisel et al. | Inhibition of hepatitis B virus DNA polymerase by 3′‐fluorothymidine triphosphate and other modified nucleoside triphosphate analogs | |
| JP2021500903A5 (cg-RX-API-DMAC7.html) | ||
| Porumb et al. | Triple-helices targeted to the polypurine tract of a murine retrovirus | |
| JP2023501352A5 (cg-RX-API-DMAC7.html) | ||
| Corneo et al. | Inhibition of DNA restriction enzyme digestion by anthracyclines | |
| HK1013257B (en) | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents |